W hen BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some ...

Q1 2025 Management View CEO Matthew Gline described the quarter as "relatively quiet" ahead of an "exciting, busy fall," ...

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

Lack of mRNA funding could pose a national security risk; CureVac, GSK settle mRNA suit against Pfizer, BioNTech; Gilead confident in HIV prevention drug prospects.

Are women somehow missing from the future of innovation? New research suggests that gender bias may be quietly shaping the ...

“Stratus,” originally known as Variant XFG, is the second most prominent strain of COVID in the United States. According to ...

The suspected gunman in the attack that killed a police officer near the Emory University campus and the CDC's headquarters ...

This week in Other Barks & Bites: the USPTO terminates 52,000 trademark applications and registrations via sanctions; the ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

The rapid rise of the SARS-CoV-2 variant XFG this summer could make it the dominant strain by the start of the fall COVID ...